87 related articles for article (PubMed ID: 32367440)
1. Immune suppression caused by PD-L2 expression on tumor cells in gastric cancer.
Nakayama Y; Mimura K; Kua LF; Okayama H; Min AKT; Saito K; Hanayama H; Watanabe Y; Saito M; Momma T; Saze Z; Ohki S; Suzuki Y; Ichikawa D; Yong WP; Kono K
Gastric Cancer; 2020 Nov; 23(6):961-973. PubMed ID: 32367440
[TBL] [Abstract][Full Text] [Related]
2. MFSD2A potentiates gastric cancer response to anti-PD-1 immunotherapy by reprogramming the tumor microenvironment to activate T cell response.
Zhang B; Wang CM; Wu HX; Wang F; Chai YY; Hu Y; Wang BJ; Yu Z; Xia RH; Xu RH; Cao XT
Cancer Commun (Lond); 2023 Oct; 43(10):1097-1116. PubMed ID: 37539769
[TBL] [Abstract][Full Text] [Related]
3. Gut microbiome-derived butyrate inhibits the immunosuppressive factors PD-L1 and IL-10 in tumor-associated macrophages in gastric cancer.
Lee SY; Jhun J; Woo JS; Lee KH; Hwang SH; Moon J; Park G; Choi SS; Kim SJ; Jung YJ; Song KY; Cho ML
Gut Microbes; 2024; 16(1):2300846. PubMed ID: 38197259
[TBL] [Abstract][Full Text] [Related]
4. PD-L2 expression in senescent cancer cells limits tumor clearance after chemotherapy.
Nat Cancer; 2024 Mar; 5(3):382-383. PubMed ID: 38332108
[No Abstract] [Full Text] [Related]
5. Publisher Correction: Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance.
Park JS; Gazzaniga FS; Wu M; Luthens AK; Gillis J; Zheng W; LaFleur MW; Johnson SB; Morad G; Park EM; Zhou Y; Watowich SS; Wargo JA; Freeman GJ; Kasper DL; Sharpe AH
Nature; 2023 Jun; 618(7966):E27. PubMed ID: 37264079
[No Abstract] [Full Text] [Related]
6. Current status of immune checkpoint inhibitors for gastric cancer.
Kono K; Nakajima S; Mimura K
Gastric Cancer; 2020 Jul; 23(4):565-578. PubMed ID: 32468420
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 overexpression in EBV-positive gastric cancer is caused by unique genomic or epigenomic mechanisms.
Nakano H; Saito M; Nakajima S; Saito K; Nakayama Y; Kase K; Yamada L; Kanke Y; Hanayama H; Onozawa H; Okayama H; Fujita S; Sakamoto W; Saze Z; Momma T; Mimura K; Ohki S; Goto A; Kono K
Sci Rep; 2021 Jan; 11(1):1982. PubMed ID: 33479394
[TBL] [Abstract][Full Text] [Related]
8. Combined inhibition of PD-1/PD-L1, Lag-3, and Tim-3 axes augments antitumor immunity in gastric cancer-T cell coculture models.
Mimura K; Kua LF; Xiao JF; Asuncion BR; Nakayama Y; Syn N; Fazreen Z; Soong R; Kono K; Yong WP
Gastric Cancer; 2021 May; 24(3):611-623. PubMed ID: 33611641
[TBL] [Abstract][Full Text] [Related]
9. Resistance to FGFR1-targeted therapy leads to autophagy via TAK1/AMPK activation in gastric cancer.
Peng R; Chen Y; Wei L; Li G; Feng D; Liu S; Jiang R; Zheng S; Chen Y
Gastric Cancer; 2020 Nov; 23(6):988-1002. PubMed ID: 32617693
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Significance of PD-1, PD-L1 and CD8 Gene Expression Levels in Gastric Cancer.
Ito S; Masuda T; Noda M; Hu Q; Shimizu D; Kuroda Y; Eguchi H; Tobo T; Utsunomiya T; Mimori K
Oncology; 2020; 98(7):501-511. PubMed ID: 32380498
[TBL] [Abstract][Full Text] [Related]
11. Biomarker-oriented chemo-immunotherapy for advanced gastric cancer.
Kono K; Nakajima S; Mimura K
Int J Clin Oncol; 2024 Apr; ():. PubMed ID: 38647874
[TBL] [Abstract][Full Text] [Related]
12. Programmed cell death-ligand 2: new insights in cancer.
Yang Y; Yan X; Bai X; Yang J; Song J
Front Immunol; 2024; 15():1359532. PubMed ID: 38605944
[TBL] [Abstract][Full Text] [Related]
13. Integrated single-cell RNA sequencing analysis reveals a mesenchymal stem cell-associated signature for estimating prognosis and drug sensitivity in gastric cancer.
Shen K; Chen B; Gao W
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11829-11847. PubMed ID: 37410142
[TBL] [Abstract][Full Text] [Related]
14. Immunology and immunotherapy in gastric cancer.
Xu X; Chen J; Li W; Feng C; Liu Q; Gao W; He M
Clin Exp Med; 2023 Nov; 23(7):3189-3204. PubMed ID: 37322134
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab versus irinotecan as third- or later-line treatment for advanced gastric cancer: a multi-center retrospective study.
Kumanishi R; Kadowaki S; Mitani S; Matsushima T; Ogata T; Narita Y; Masuishi T; Bando H; Tajika M; Yasui H; Hara H; Muro K
Int J Clin Oncol; 2023 Jun; 28(6):756-763. PubMed ID: 36943545
[TBL] [Abstract][Full Text] [Related]
16. Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy.
Wang Y; Du J; Gao Z; Sun H; Mei M; Wang Y; Ren Y; Zhou X
Br J Cancer; 2023 Mar; 128(7):1196-1207. PubMed ID: 36522474
[TBL] [Abstract][Full Text] [Related]
17. Immune-Related LncRNAs to Construct a Prognosis Risk-Assessment Model for Gastric Cancer.
Zhi S; Yang B; Zhou S; Tan J; Zhong G; Han F
Curr Oncol; 2022 Jul; 29(7):4923-4935. PubMed ID: 35877251
[TBL] [Abstract][Full Text] [Related]
18. PD-L2 Serves as a Potential Prognostic Biomarker That Correlates With Immune Infiltration and May Predict Therapeutic Sensitivity in Lower-Grade Gliomas.
Xie Q; Huang X; Huang W; Liu F
Front Oncol; 2022; 12():860640. PubMed ID: 35756621
[TBL] [Abstract][Full Text] [Related]
19. FasL
Shan ZG; Zhao YL; Zhang JY; Yan ZB; Wang TT; Mao FY; Teng YS; Peng LS; Chen WY; Wang P; Cheng P; Tian WQ; Chen J; Chen W; Zhuang Y
Adv Sci (Weinh); 2022 Feb; 9(5):e2103543. PubMed ID: 34957697
[TBL] [Abstract][Full Text] [Related]
20. The Positive and Negative Immunoregulatory Role of B7 Family: Promising Novel Targets in Gastric Cancer Treatment.
Bolandi N; Derakhshani A; Hemmat N; Baghbanzadeh A; Asadzadeh Z; Afrashteh Nour M; Brunetti O; Bernardini R; Silvestris N; Baradaran B
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
